Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)
-
Published:2024-08
Issue:4
Volume:22
Page:102099
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Gambale Elisabetta, Maruzzo MarcoORCID, Messina CarloORCID, De Gennaro Aquino Irene, Vascotto Ismaela Anna, Rossi Virginia, Bimbatti Davide, Cavasin Nicolò, Messina Marco, Mennitto AlessiaORCID, Rebuzzi Sara ElenaORCID, Nasso Cecilia, Mercinelli ChiaraORCID, Maiorano Brigida AnnaORCID, Fanelli MartinaORCID, Sorarù MariellaORCID, Scolari FedericoORCID, Mela Marinella Micol, Galli LucaORCID, Salfi Alessia, Rizzo Mimma, Puglisi Silvia, Orlando Valentina, Fornarini Giuseppe, Rametta Alessandro, Giannatempo Patrizia, Cerbone Linda, Doni Laura, Roviello Giandomenico, Pillozzi Serena, Antonuzzo Lorenzo
Reference40 articles.
1. Epidemiology of bladder cancer;Saginala;Med Sci (Basel),2020 2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000 3. Emerging immunotherapies for bladder cancer;Kim;Curr Opin Oncol,2015 4. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after ≥2 years of follow-up;Powles;J Clin Oncol,2023 5. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab;Martens;Clin Cancer Res,2016
|
|